Background: Flow diversion with the Pipeline embolization device (PED) is an effective neuroendovascular method and increasingly accepted for the treatment of cerebral aneurysms. Acute in situ thrombosis is a known complication of PED procedures. There is limited experience in the flow diversion literature on the use of abciximab (ReoPro) for the management of acute thrombus formation in PED cases. Methods: Data were collected retrospectively on patients who received intra-arterial (IA) ReoPro with or without subsequent intravenous (IV) infusion during PED flow diversion treatment of intracranial aneurysms. Results: A total of 30 cases in patients with a mean age of 56.7 years (range 36-84) and a mean aneurysm size of 8.6 mm (range 2-25) were identified to have intraprocedural thromboembolic complications during PED treatment. IA ReoPro was administered in all cases, with 20 cases receiving increments of 5-mg boluses and 10 cases receiving a 0.125 mg/kg IA bolus (half cardiac dosing). Complete or partial recanalization was achieved in 100% of the cases. IV ReoPro infusion at 0.125 μg/kg/min for 12 h was administered postprocedurally in 22 cases with a residual throm- bus. Postprocedurally, 18 patients were transitioned from clopidogrel (Plavix) to prasugrel (Effient). The majority of the cases (23/30; 77%) were discharged home. Periprocedural intracranial hemorrhage was noted in 2 cases (7%) and radiographic infarct was noted in 4 cases (13%), with an overall mortality of 0% at the time of initial discharge. Clinical follow-up was available for 28/30 patients. The average duration of follow-up was 11.7 months, at which time 23/28 (82%) of the patients had a modified Rankin Scale score of 0. Conclusions: IA ReoPro administration is an effective and safe rescue strategy for the management of acute intraprocedural thromboembolic complications during PED treatment. Using a dosing strategy of either 5-mg increments or a 0.125 mg/kg IA bolus (half cardiac dosing) can provide high rates of recanalization with low rates of hemorrhagic complications and long-term morbidity.
Introduction
The Pipeline embolization device (PED; Medtronic Neurovascular, Irvine, CA, USA) and the second-generation PED Flex (Medtronic Neurovascular) have become increasingly pertinent modalities in the modern management of cerebral aneurysms [1] [2] [3] . The safety and efficacy of the PED have been demonstrated in both immediate and long-term outcome studies [2, [4] [5] [6] [7] . Dual antiplatelet therapy is routinely used to mitigate known thromboembolic risks. The reported overall ischemic stroke risk for patients undergoing PED treatment ranges from 3 to 6% while on maintenance with dual antiplatelet therapy [1, 8, 9] . Acute intraprocedural thrombus formation during PED procedures remains a significant challenge [10, 11] . This phenomenon is postulated to be due to platelet aggregation because of the high metal density of the device in conjunction with a patient's metabolic hyporesponsiveness to preprocedural dual antiplatelet therapy. Studies attempting to quantify and predict the risk of periprocedural thromboembolic events using the P2Y12 receptor inhibition assay have been inconclusive [8, 10] . Furthermore, there is no clear consensus or evidence-based protocol for the management of acute thrombus formation during PED embolization cases.
Abciximab (ReoPro; Eli Lilly and Co., Indianapolis, IN, USA), a glycoprotein (GP) IIb/IIIa inhibitor, is utilized as a rescue therapy for thromboembolic complications during intracranial aneurysm coil embolization. Several studies suggest that full cardiac dosing of intraarterial (IA) ReoPro can successfully resolve the acute thrombus and provide flow restoration without increasing the risk of intracranial hemorrhage [12] [13] [14] . Experience with ReoPro for acute intraprocedural platelet aggregation in flow diversion is limited, with only two small case series to date [10, 15] . In each of these series, the delivery method, indication, and dosing algorithm for ReoPro were not standardized. Furthermore, long-term clinical and radiographic outcomes were lacking in these series.
Here, in this report, we identified all neurointerventions where IA ReoPro was administered for the treatment of acute thrombus formation during PED procedures. We hypothesized that a low-dose IA ReoPro bolus, with or without intravenous (IV) maintenance, was sufficient to mitigate periprocedural clinical ischemic complications with a low risk of intracranial hemorrhage.
Methods

Patient Selection
This was an institution-based, nonrandomized, retrospective cohort study of a prospectively collected database of intracranial aneurysms treated at a single institution in the USA (The Johns Hopkins Medical Institute, Baltimore, MD, USA). Adult patients treated with the PED and PED Flex (including both anterior and posterior circulation aneurysms with and without previous rupture/treatment) from April 2011 to May 2017 were identified in an IRB-approved database. Cases where acute intraprocedural thrombus formation was encountered and treated with ReoPro (IA, IV, or both) were selected for the study.
Data Collection
Data on patient demographics, aneurysm characteristics, proximal vessel tortuosity (of the cervical internal carotid artery (ICA) and cavernous carotid artery, as previously defined [16, 17] ), modified Rankin Scale (mRS) scores (at the time of discharge and at the last follow-up), discharge disposition, PED specifications, dosing of IA ReoPro, dosing of IV ReoPro, the amount of IV heparinization, preoperative antiplatelet agents, and the postprocedural antiplatelet regimen were collected. Periprocedural details including radiographic evaluation of thrombus resolution, radiographic incidence of new ischemia, and/or acute intracranial hemorrhage were recorded. The data are presented as counts, percentages, and means. When means are presented, the standard error of the mean (SEM) is used to assess the sample distribution.
Endovascular Procedure
The patients were typically treated preoperatively with daily aspirin 325 mg and clopidogrel 75 mg for 7 days. Platelet inhibition testing was not routinely used. Endovascular procedures were performed on a biplanar flat panel angiographic system (Artis Zee; Siemens, Erlangen, Germany) under general anesthesia. Intraprocedural systemic anticoagulation was administered with an initial IV heparin bolus of 5,000 units followed by 1,000 units per subsequent hour. For all cases, a triaxial system (long guide sheath, distal intracranial catheter, and microcatheter) was used through an 8-Fr-short-sheath femoral access. The PED was deployed under real-time visualization using native fluoroscopy (7.5 pulses/s), Road Map, and digital subtraction angiography (DSA; 3 frames/s). Control DSA was performed immediately after deployment as well as 5 and 10 min after deployment to confirm vessel wall apposition and parent vessel patency and to rule out acute intraluminal thrombi.
If acute thrombus formation was noted on DSA, an IA ReoPro bolus of either 5 mg or 0.125 mg/kg (half cardiac dose) based on the ideal body weight was directly infused through the triaxial system. Concurrently, either 1,000 or 2,000 units of IV heparin were administered. Control DSA was performed at 5-min intervals after the IA ReoPro bolus. If a significant thrombus persisted on radiographic imaging, an additional 5-mg or 0.125 mg/kg IA ReoPro bolus was given a maximum of 2 additional times. In cases with complete recanalization after IA ReoPro treatment, IV ReoPro was not used postprocedurally. If a residual thrombus was present after the IA bolus, then IV ReoPro infusion at a rate of 0.125 μg/kg/min was initiated immediately and continued for 12 h after the procedure.
After each case, DynaCT without contrast was performed to further assess device opening and to rule out intracranial hemorrhage. After the procedure, all patients were admitted to the neurocritical care unit. The femoral arterial sheath was removed the following day. Daily aspirin 325 mg was continued for the majority of patients. For those patients without medical or logistical contraindications, daily prasugrel (Effient) 5 or 10 mg (based on the body mass index) was initiated and clopidogrel was discontinued. The patients were seen in follow-up at 1 month and 6 and 12 months. Follow-up cerebral angiography was performed at 6 and 12 months.
Results
During the study period of April 2011 to May 2017, a total of 680 PED/PED Flex procedures were performed for the treatment of intracranial aneurysms. Of these 680 PED cases, only 30 were identified where an acute thrombus had formed intraprocedurally and had been treated with IA ReoPro. The case summaries for these 30 PED procedures are presented in Tables 1 and 2 .
Patient and Aneurysm Characteristics
The mean patient age was 58 years (range 37-85), with the majority (26/30; 87%) of the patients being female. The mean aneurysm size was 8.6 mm (range 2-25), with small aneurysms (< 10 mm) accounting for 63% (19/30) of the cases. Most of the aneurysms (27/30; 90%) were in the anterior circulation. Internal carotid artery aneurysms along the ophthalmic/ paraophthalmic segment were the most common (10/30; 33%). Only 3 cases were posterior circulation aneurysms (2 in the superior cerebellar artery and 1 in the basilar apex). Five cases were previously treated aneurysms (4 coiled and 1 flow diverted), with subsequent residuals/recurrence requiring additional treatment.
Proximal Vascular Access Characteristics
Of the 27 cases of anterior circulation aneurysm, 12 (44%) had significant cervical ICA tortuosity and 11 (41%) had moderate-to-severe cavernous ICA tortuosity characterized by a cavernous ICA grade of II-IV [17] . The 0.058″ AXS Catalyst 5 (Stryker Neurovascular, Fremont, CA, USA) and 0.058″ Navien (Medtronic Neurovascular) were the most frequently utilized distal intracranial catheters. The most common distal intracranial catheter position was along the cavernous segment of the ICA. Verapamil infused intra-arterially was used in 5 (17%) of the cases to treat catheter-induced vasospasm. Values are presented as n (%) unless stated otherwise. PCOM, posterior communicating. (Fig. 1) . In 22 cases with partial recanalization after IA ReoPro treatment, postproce- 
Procedural Details
Ischemic or Hemorrhagic Complications
In the majority (23/30; 77%) of the cases, the patients were discharged home on either postoperative day (POD) 1 or 2. At the time of discharge, 23/30 (77%) had an mRS score of 0, 3/30 had an mRS score of 3 (1 was baseline preprocedurally), and 4/30 had an mRS score of 4 (1 was baseline preprocedurally). Of the 5 patients with a discharge mRS score > 0, without any preexisting disability at baseline, only 4 (cases No. 6, 10, 17, and 19) had ischemic infarcts (Fig. 3) .
Intracranial hemorrhage occurred in only 2 cases (7%) (Fig. 4) . Case No. 6 was a sexagenarian with a previously coiled, 5-mm, ruptured right posterior communicating artery aneurysm. During PED treatment of aneurysm recurrence, in-stent thrombosis and subsequent flow limitation in the right anterior cerebral artery (ACA) was noted. A total of 10 mg IA ReoPro was administered, with marked resolution of the thrombus and recanalization of the right A1 segment as well as the distal ACA territory. A postprocedural routine head CT revealed multifocal intracerebral hemorrhage (ICH), largest in a hypodense region of the right caudate head, likely representing hemorrhagic transformation of an acute infarction. Clopidogrel was maintained for 3 days, while daily aspirin 325 mg was continued. The patient was subsequently discharged to a rehabilitation facility on POD4 with an mRS score of 4 and has subsequently been lost to follow-up. Case No. 14 was a septuagenarian who presented with a Glasgow Coma Scale score of 10 with a ruptured, 4-mm left posterior communicating artery aneurysm which was treated at the time with coil embolization. The patient was eventually discharged to a rehabilitation facility with an mRS score of 3. Follow-up angiography showed a residual aneurysm in the neck for which PED treatment was recommended. During PED deployment, device malposition was noted, requiring balloon angioplasty to improve vessel wall apposition. After the angioplasty procedure, in-stent thrombosis developed. A total of 10 mg IA ReoPro was administered with partial recanalization. IV ReoPro infusion was initiated after the procedure. The patient subsequently developed left upper extremity weakness, and a head CT revealed a 16-cm 3 right parietal-occipital ICH. The patient's IV ReoPro infusion was maintained and an operative intervention was not necessary. The patient was discharged to rehabilitation on POD6 with a stable mRS score of 3. By the last follow-up at 5.8 months, the patient had completely recovered with an mRS score of 0 and received medical clearance to drive a motor vehicle.
Long-Term Clinical Follow-Up
Twenty-eight patients underwent clinical follow-up for an average of 11.7 months. At the last clinical follow-up, 23/28 (82%) of the patients had an mRS score of 0. Of the 5 patients with a follow-up mRS score > 0, 4 had a stable or improved mRS score when compared to their discharge score. For example, Figure 5 illustrates case No. 19, a quinquagenarian who underwent coil-assisted PED treatment of a 9-mm right A2-3 ACA aneurysm, complicated by in-stent and pericallosal artery thrombosis. A total of 20 mg IA ReoPro was administered with near-complete radiographic resolution of the thrombus. The patient was maintained on IV ReoPro infusion postprocedurally, but was noted to have new-onset left-sided weakness. Head CT, CT angiography, and repeat diagnostic angiography on POD1 did not reveal any large vessel occlusion, in-stent thrombosis, or acute hemorrhage. The patient's weakness persisted, and a follow-up MRI demonstrated multiple small infarcts in the right ACA subcortical and watershed territory. The patient was managed expectantly and was discharged with an mRS score of 4, unable to ambulate. By the 2.6-month follow-up, the patient had regained ambulatory function with an mRS score of 3.
One delayed death was encountered in this series. Case No. 17 was a sexagenarian with chronic kidney disease and congestive heart failure found incidentally with a 9-mm, irregularly contoured right middle cerebral artery (MCA) bifurcation aneurysm. During coil-assisted PED embolization, a small platelet plug was visualized in the proximal portion of the device and 5 mg of IA ReoPro was administered with subsequent improvement. Postprocedurally, the patient had grade 0-1 strength (out of 5) in the left upper and lower extremities. Repeat angiography showed a widely patent right MCA and PED construct. Head CT on POD1 and 2 showed a diffuse cerebral edema in the right hemisphere consistent with a contrast reaction without infarction. Head CT on POD3 demonstrated a small right basal ganglion infarct. The patient was discharged to a rehabilitation facility with an mRS score of 4, then was briefly admitted 3 months later for seizures and a negative radiographic workup. Unfortunately, only 4 days after that hospitalization, the patient was found unresponsive and head CT revealed a large left basal ganglion ICH with significant intraventricular hemorrhage and hydrocephalus. This injury was on the contralateral side of the prior procedure and was likely a hemorrhagic conversion of a new infarct. Considering the patient's poor neurological prognosis, the family elected for comfort care and the patient expired from this unrelated injury.
Discussion
Thromboembolic complications are known risks of endovascular treatment for cerebral aneurysms, with reported rates ranging from 2 to 15% for coiling alone, and from 4 to 20% for stent-assisted coiling and flow diversion [18, 19] . Dual antiplatelet therapy is routinely prescribed periprocedurally to mitigate this ischemic infarct risk during stent-assisted coiling and flow diversion treatments. Due to the higher metal density of flow diverters compared to the traditional intracranial stents for coiling, adjunct preprocedural platelet inhibition testing was proposed to assist with thromboembolic risk stratification, but this remains a controversial subject within the flow diversion literature [8, 10] . A recent retrospective multicenter study by Adeeb et al. [20] defined clopidogrel nonresponders as having a P2Y12 level > 208 and concluded that the rate of thromboembolic complications in PED cases for this group was 17.4% versus 5.6% for the clopidogrel responders (P2Y12 reaction units [PRU] < 208). In contrast, Bender et al. [8] evaluated a series of 52 patients with a P2Y12 level > 200 undergoing PED treatment for intracranial aneurysms and found the rate of thromboembolic complications to be only 4%, concluding that this "nonresponder" level was not associated with increased thromboembolic complications in anterior circulation PED treatments. While a consensus on preembolization antiplatelet dose titration and platelet inhibition testing for PED procedures is not imminent, rapid rescue therapy for intraprocedural platelet plug and thrombus formation is an essential tool for the neurointerventionalist in not only PED treatments but any intracranial stent procedures. Abciximab (ReoPro; Eli Lilly) is the most widely used GP IIb/IIIa inhibitor for rescue therapy in the endovascular literature. GP IIb/IIIa inhibitors act by preventing fibrinogen from binding to the GP IIb/IIIa receptor, thus preventing platelet activation, aggregation, and plug/thrombus formation. ReoPro is a monoclonal human antibody with a high receptor affinity and long duration of action. Initial experience with ReoPro began in the cardiac field, and it has long been established with a dosing regimen of IV ReoPro boluses of 0.25 mg/kg followed by an infusion rate of 0.125 μg/kg/min [21, 22] . In the neuroendovascular coil embolization literature, the dosing and administration regimens for ReoPro have been heterogeneous and extremely variable [12] [13] [14] . Some studies utilized 2-5 mg IA incremental boluses [23, 24] , others used a full cardiac loading dose at 0.25 mg/kg (IA or IV) [13, 25] , and some used a combination of the above with continuous IV infusion after the initial IA bolus [26, 27] . A review of the key studies on this topic was aptly performed by Dornbos et al. [28] . The authors summarized that despite the high variability in dosing and administration regimens, the overall recanalization rates were 72-100%, with rates of ICH as low as 2-3% [12-14, 23, 24, 26, 28, 29] and as high as 18%, with 44% mortality [30] . Dornbos et al. [28] recommend a ReoPro dosing strategy of an initial 0.25 mg/kg (full cardiac dose) bolus, given IA or IV, followed by continuous IV infusion of 0.125 μg/kg/min maintained for 12 h [28, 30] .
The experience with ReoPro administration in the flow diversion literature for the management of intraprocedural acute thrombus formation is quite limited, with only 2 small case series to date [10, 15] . In the series by Patel et al. [10] , 2 patients received half the cardiac weight-based loading dose and 3 patients received the full dose. All 5 patients had immediate recanalization; therefore, postprocedural IV maintenance was not administered. All 5 patients had an mRS score of 0 at discharge and follow-up. Interestingly, the group noted that 4 of the 5 patients had a P2Y12 value > 200. In the series by Lall et al. [15] , 3 patients with acute thrombosis after PED deployment were treated with the full cardiac 0.25 mg/kg loading bolus and had prompt recanalization with no postprocedural clinical complications.
Compared to the above studies, our case series is on par with the coil embolization literature with respect to the rate of hemorrhagic and ischemic complications (7 and 13%, respectively). Our clinical outcomes are similar to those in the PED series by Patel et al. [10] and Lall et al. [15] , achieving immediate complete or partial recanalization in all 30 cases. Additionally, all but 1 patient in our series had a follow-up mRS score that was stable or improved compared to discharge, and 23/28 (82%) had an mRS score of 0 at the last follow-up. Our dosing strategy mirrored the coiling literature in 20 cases where we used increments of 5-mg IA boluses. For 10 cases, we used incremental 0.125 mg/kg IA loading boluses, which is half the commonly utilized 0.25 mg/kg dose found in the coil embolization and cardiac literature. In our weightbased loading bolus group, no ischemic or hemorrhagic complications were encountered. Interestingly, the 2 hemorrhagic complications in our series occurred in the 5-mg-increment group, with 2 patients who had recent subarachnoid hemorrhage. Of note, the 5-mg IA bolus dose is a lower dose than the 0.125 mg/kg loading dose based on an average body weight of 70 kg (which would entail 8.75 mg). Our data suggest that starting with a lower loading IA bolus dose than commonly reported in the literature may be sufficient for thrombus resolution and recanalization, without increasing the rate of postprocedural ischemic infarcts, and minimizing the hemorrhagic risk.
We have since strategized a standardized protocol for dosing IA and IV ReoPro rescue treatment of intraprocedural acute thrombus formation in PED embolization procedures. Figure 6 illustrates this protocol, which includes the imaging details needed to evaluate thrombus resolution, the timing of IV ReoPro infusion, and nuances of postprocedural care including femoral sheath management and an antiplatelet strategy. Systemic heparin infusion was utilized in the infancy of this experience (2011) (2012) (2013) , when the ReoPro literature in the neuroendovascular field was still in the early stages. To avoid potential hemorrhagic complications in cases of partial recanalization, we no longer use dual IV heparin and ReoPro infusion. To rapidly and urgently implement the protocol outlined in Figure 6 , the neuroendovascular suite Pyxis must have ReoPro stocked and readily accessible. Postprocedurally, all patients in our series were admitted to a dedicated neurocritical care unit for intensive monitoring. We also prefer maintaining femoral arterial sheath placement overnight, as its immediate removal following ReoPro administration can lead to increased risks for groin hematoma and retroperitoneal hemorrhage. Additionally, an indwelling sheath in the acute postoperative period provides rapid access to repeat angiography if clinically indicated. We connect the femoral sheath to a transducer, while an arterial line waveform is displayed on the monitor as a safety measure. Given both the inconclusive P2Y12 literature and the fact that the assay results are affected by ReoPro administration, we transition patients' antiplatelet regimen from aspirin and clopidogrel dual therapy to aspirin and another adenosine diphosphate receptor inhibitor (prasugrel, ticlopidine, or ticagrelor) unless medical or logistical contraindications exist. On postprocedural day 1, we routinely start 5 mg of prasugrel (Effient) for patients with a normal weight to overweight, and 10 mg prasugrel for patients with a BMI in the obese range, sans loading dose, to be continued as an outpatient. During the study time period of April 2011 to May 2017, a total of 680 PED embolization procedures were performed at our institution. All patients were preoperatively treated with daily aspirin 325 mg. For the second antiplatelet, daily clopidogrel 75 mg was used in 670 cases, daily prasugrel 5 or 10 mg (weight based) was used in 8 cases, and ticagrelor 90 mg twice daily was used in 2 cases. Only 30 of the 680 PED cases developed acute thrombus formation intraprocedurally, with a calculated in situ thrombosis risk of 4.4%. Furthermore, of this 30-case subgroup with intraprocedural acute thrombus formation, only 4 were complicated by ischemic infarcts. Interestingly, 3 of these 4 cases were treatments for aneurysms located beyond the ICA (2 in the ACA and 1 in the MCA). Considering that only a fraction (4/680 total; 0.6%) of these patients suffered an embolic complication, this observed rate is superior to the 3-6% risk of thromboembolic complications for PED treatments reported in previous studies [1, 8, 9] . We have previously reported a similar rate of thromboembolic complications in patients with high P2Y12 levels (PRU > 200), considered as "nonresponders" [8] . As such, we continue to strongly caution against preprocedural titration of antiplatelet medications to P2Y12 levels, given the likelihood of increasing hemorrhagic risks with this practice.
ReoPro is the GP IIb/IIIa inhibitor of choice for rescue therapy at our institution. Eptifibatide (Integrilin), an alternative GP IIb/IIIa inhibitor, is preferentially used at various centers. In comparison to ReoPro, eptifibatide is a small-molecule GP IIb/IIIa inhibitor with a shorter pharmacokinetic half-life, which allows for rapid return of platelet function in the event of hemorrhagic complications. Ramakrishnan et al. [31] utilized incremental loading doses starting at 25% of a 90 μg/kg IA bolus, followed by 0.5 μg/kg/min IV infusion for 20 aneurysm patients, with a 97.5% complete or partial recanalization rate and 0% intracranial hemorrhage. Similarly, Sedat et al. [32] reported a 91% recanalization rate, without any incidence of intracranial hemorrhage, in a 45-patient aneurysm cohort using a single IA 0.2 mg/ kg eptifibatide bolus. The review by Dornbos et al. [28] of GP IIb/IIIa inhibitor use in endovascular treatments of aneurysms recommends using a 90 μg/kg IA bolus, followed by 0.5 μg/kg/min IV infusion for 12 h for rescue therapy. The protocol established in this study uses the lowest effective bolus of IA ReoPro followed by IV infusion, if necessary, and can similarly be applied to eptifibatide administration.
The limitations of the current study are due to its retrospective, single-institution nature. There is also heterogeneity in ReoPro dosing within our series. As a result, our recommendations for best practice guidelines are as specified in Figure 6 . Prospective, randomized studies will be required to establish further protocols.
Conclusion
IA ReoPro administration is an effective and safe strategy for the management of acute in situ thrombogenic complications during PED treatment. Remarkably, high rates of immediate thrombus resolution can be achieved with half the cardiac and coil embolization bolus dosage (0.125 mg/kg) or even less. We recommend incremental IA boluses of 0.125 mg/kg for major acute thrombus formation, and 5-mg increment boluses for minor thrombi. Post-Intracranial Aneurysms www.karger.com/ine © 2018 S. Karger AG, Basel DOI: 10.1159/000486458 procedural IV ReoPro infusion is necessary in cases where IA boluses of ReoPro result only in partial recanalization. Such a careful dose escalation methodology provides relatively low rates of hemorrhagic complications with high recanalization rates, and yields optimal longterm clinical outcomes.
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